Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2025 Jan;132(1):49-50.
doi: 10.1038/s41416-024-02933-y. Epub 2024 Dec 16.

Commentary to: Cancer and treatment specific incidence rates of immune related adverse events induced by immune checkpoint inhibitors: a systematic review

Alessandro Villa  1   2 , Bryan J Schneider  3 , Christina Lacchetti  4 , Thomas K Oliver  4 , Douglas E Peterson  5
Affiliations
Comment

Commentary to: Cancer and treatment specific incidence rates of immune related adverse events induced by immune checkpoint inhibitors: a systematic review

Alessandro Villa et al. Br J Cancer. 2025 Jan.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing interests: The authors declare no competing interests.

Comment on

References

    1. Jayathilaka B, Mian F, Franchini F, Au-Yeung G, IJzerman M. Cancer and treatment specific incidence rates of immune-related adverse events induced by immune checkpoint inhibitors: a systematic review. Br J Cancer. 2024; 10.1038/s41416-024-02887-1. Online ahead of print. - PMC - PubMed
    1. Harris JA, Huang K, Miloslavsky E, Hanna GJ. Sicca syndrome associated with immune checkpoint inhibitor therapy. Oral Dis. 2022;28:2083–92. - DOI - PubMed
    1. Vigarios E, Epstein JB, Sibaud V. Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors. Support Care Cancer. 2017;25:1713–39. - DOI - PubMed
    1. Elad S, Yarom N, Zadik Y, Kuten-Shorrer M, Sonis ST. The broadening scope of oral mucositis and oral ulcerative mucosal toxicities of anticancer therapies. CA Cancer J Clin. 2022;72:57–77. - DOI - PubMed
    1. Xu Y, Wen N, Haddad RI, Sonis ST, Villa A. Comparisons of non-oral immune-related adverse events among patients with cancer with different oral toxicity profiles. Oncologist. 2024;29:e382–e91. - DOI - PMC - PubMed

LinkOut - more resources